{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Wu Zhong"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0002279000"],"submitter_email":["zhongwu@bmi.ac.cn"],"submitter_affiliation":["National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology."],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"pubmed_title":["Pathological features of COVID-19-associated liver injury-a preliminary proteomics report based on clinical samples."],"pubmed_authors":["Leng Ling L, Cao Ruiyuan R, Ma Jie J, Lv Luye L, Li Wei W, Zhu Yunping Y, Wu Zhihong Z, Wang Manli M, Zhou Yiwu Y, Zhong Wu W"],"additional_accession":[]},"is_claimable":false,"name":"Integrated Proteomics Characterization of SARS-CoV-2 Associated Liver Injury","description":"The high incidence of liver injury in patients with COVID-19 and the need for long-term medication for recovery make it imperative to study the infectivity and pathogenicity of SARS-CoV-2 in the liver. Here, we have identified significant proteomic changes for the first time in the liver of patients with COVID-19 using a quantitative proteomics approach. We detected differential expression levels of several proteins that mediate characteristic cellular host responses elicited by SARS-CoV-2 infection. These findings reveal important molecular mechanisms that may play a key role in the pathogenesis of COVID-19 associated liver diseases and provide a scientific basis for medical intervention strategy and drug target selection.","dates":{"publication":"Tue Jun 23 00:00:00 BST 2020"},"accession":"PXD019968","cross_references":{"TAXONOMY":["9606"],"pubmed":["33419962"]}}